Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Windtree Therapeutics Announces Completion of $12.9 Million Financing in Partnership with Series C Preferred Stock Holders
Jul 22, 2024•almost 2 years ago
Contract Type
partnership
PennsylvaniaBiotechnologyHealth CareTherapeuticsPharmaceuticalDescription
Windtree Therapeutics, Inc. (NasdaqCM: WINT) has closed a private placement of Series C Convertible Preferred Stock and warrants to acquire additional shares of Common Stock, resulting in aggregate gross proceeds of approximately $12.9 million, including the cancellation of outstanding notes and extinguishment of Series B Preferred Shares. Additionally, the Company established a $35 million equity line of credit.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months